A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion

Lung cancer is an important part of malignant tumors, with an annual incidence of 1,796,144 new deaths and 2,206,771 new cases in 2020 all over the world [1]. As the common histological type of lung cancer, non-small-cell lung cancer (NSCLC) mainly consists of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [2]. For early stage NSCLC patients, curative-intent anatomic surgical resection is the standard of treatment strategy, whereas the onset of recurrence and metastasis after surgery often results in treatment failure and mortality [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research